352 results about "Chemotherapy drug" patented technology

The present invention provides compositions comprising interfering RNA (e.g., siRNA, aiRNA, miRNA) that target polo-like kinase 1 (PLK-1) expression and methods of using such compositions to silence PLK-1 expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence PLK-1 expression and methods of use thereof. The present invention also provides serum-stable nucleic acid-lipid particles (e.g., SNALP) comprising an interfering RNA molecule described herein, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing PLK-1 gene expression by administering an interfering RNA molecule described herein to a mammalian subject. The present invention additionally provides methods of identifying and / or modifying PLK-1 interfering RNA having immunostimulatory properties. Methods for sensitizing a cell such as a cancer cell to the effects of a chemotherapy drug comprising sequentially delivering PLK-1 interfering RNA followed by the chemotherapy drug are also provided.

The invention discloses a tumor-targeted nanometer drug delivery system for cooperative chemotherapy and photodynamic therapy and a preparation method thereof. The drug delivery system is prepared from carboxymethyl chitosan, folate, a photosensitizer chlorine e6 and adriamycin, wherein the chlorine e6 and the folate are coupled to a carboxymethyl chitosan chain segment through an amido bond, and are loaded to polymer nanoparticles of the adriamycin through an ion exchange method. The nanometer material prepared by the method is high in yield, regular in shape and even in distribution. In-vivo and in-vitro experiments prove that the tumor targeting property of the nanometer preparation can be significantly improved by folate receptor mediation; enrichment on the tumor part is achieved and drug release is controlled. The photosensitizer is capable of effectively reversing the chemotherapy drug resistance and significantly inhibiting the growth of tumors after being irradiated by near-infrared light. Therefore, the related nanometer drug delivery system has good application prospect in the aspect of breast cancer treatment.

This invention provides herbal compositions useful for increasing the therapeutic index of drugs, including those used in the treatment of disease, especially viral infections and neoplasms of cancer. This invention provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a person undergoing such chemotherapy.

The invention provides an application of a type of berbamine derivatives and salts thereof in the preparation of drugs for the treatment of tumors, which is mainly applied in the preparation of the drugs for the prevention and treatment of nuclear transcription factor NF-kBp65 activity-related diseases and BCR / ABL transcription activity-related diseases. The drugs are combined and prepared by the compounds of the invention and one or more pharmaceutically acceptable excipients. The preparation forms comprise solid preparations, semi-solid preparations or liquid preparations. The type of berbamine derivatives and the salts thereof provided by the invention have broader and stronger anti-leukemia and anti-solid-tumor activity, the tumors proved to be sensitive are leukemia, multiple myeloma, liver cancer, osteosarcoma and breast cancer; the toxicity and the side effects are lighter. An in vitro cell culture system and animal experiments confirm that the berbamine derivatives and the salts thereof have no significant toxicity or side effects to the growth of normal human hematopoietic cells and experimental animals under the anti-tumor dosage, which are superior to the commonly used chemotherapy drugs.

The present invention discloses combinations of drug conjugates with other therapeutic agents, including chemotherapy drugs. The invention also provides methods of using the combinations for the treatment of diseases associated with cell proliferation, such as tumors.

A mouse monoclonal antibody for antagonizing and inhibiting binding of a vascular endothelial cell growth factor (VEGF) and its receptor (VEGF-R), and a heavy chain variable region and light chain variable region amino acid sequence thereof. Also disclosed are a humanized preparation process of the antibody and a heavy chain variable region and light chain variable region amino acid sequence of the humanized antibody. The humanized antibody or its derivative can act as an ingredient of a pharmaceutical composition or be prepared into a suitable pharmaceutical preparation, is administered alone or in combination with a chemotherapy drug or other treatment means, and is used in broad-spectrum treatment of various solid tumors such as colon cancer, breast cancer and rhabdomyosarcoma.

An anticancer vaccine of recombinant human MOC1-MBP fusion protein is disclosed, in which MBP is used as its adjuvant. The MBP gene and MUC1 gene are fused together. The MBP substituted for other fusion protein to induce CTL reaction. The pMAL-P2 is the carrier for effectively expressing maltose fusion protein. The serial repetitive sequence of MUC1 is inserted to downstream of malE gene.

The invention relates to a novel multifunctional nano diagnosis and treatment agent based on tumor multi-mode co-therapy and a preparation method thereof. The multifunctional nano diagnosis and treatment agent comprises a silicon dioxide casing provided with a cavity and mesoporous channels, gadolinium-mixed upconversion fluorescence nano particles adopting core-shell structures and located in the cavity of the silicon dioxide casing, chemotherapy drug, which is loaded between the silicon dioxide casing and the gadolinium-mixed upconversion fluorescence nano particles, and has sensibilization effect on radiation treatment, and photosensitizer, which is loaded in the mesoporous channels in the silicon dioxide casing.

This invention provides herbal compositions useful for increasing the therapeutic index of drugs, including those used in the treatment of disease, especially viral infections and neoplasms of cancer. This invention provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a person undergoing such chemotherapy.

The present invention relates to therapeutic conjugates with the ability to target various antigens. The conjugate contains a targeting antibody or an antigen-binding fragment thereof and an anthracycline chemotherapy drug. The targeting antibody and the anthracycline chemotherapy drug are linked via a linker that includes a hydrazide moiety.

The invention belongs to the genetic engineering field, and especially relates to an application of long-chain non-coding RNA in the preparation of non-small cell lung cancer treatment drugs. The change of the lnc-uc002llc.1 expression has influences on the apoptosis, proliferation, the drug susceptibility and the like of non-small cell lung cancer cells, so the reduction of the lnc-uc002llc.1 expression can realize the apoptosis promotion, proliferation inhibition and chemotherapy drug susceptibility enhancement of the non-small cell lung cancer cells.

The invention discloses an environmentally responsive tumor targeted combined administration transfer system.Adriamycin amycin and carboxymethyl chitosan are connected through a disulfide bond, and therefore an adriamycin amycin macromolecular prodrug is synthesized.The other chemotherapy drug is ingeniously encapsulated in the adriamycin amycin macromolecular prodrug, and therefore the combined administration nano transfer system is prepared.The system has good systemic circulation stability and intelligent drug release performance, few drug ingredients are released in simulated blood, the release quantity of the drug ingredients in a cancer cell environment is very large, and meanwhile high applicability is achieved.

The invention discloses a high throughput sequencing method for detecting genes of multiple mutant types and applications thereof, and belongs to the field of gene detection. By searching database, variation sites of genes for a cancer target treatment, chemotherapy drug resistant genes, and chemotherapy drug sensitive genes, 100 bp of downstream of the variation sites, and 100 bp of upstream of the variation sites are taken as a target section; a capture probe matched with the target section is synthesized, the target area of DNA of a sample is captured, a high throughput sequencing library is established; then high throughput sequencing is carried out to obtain the sequence of a target section; and the results of cancer related gene mutation, insertion mutation, delete mutation, mutationof copy number, and gene fusion mutation can be obtained. The provided method can detect multiple kinds of mutations of 105 cancer related genes at a time and has the characteristics of high capturing efficiency and good uniformity.

The invention relates to a biological nanometer magnetic target anti-cancer drug, which is formed by coupled biological nanometer magnetic smalls and anti-cancer chemical drug. Wherein, the biological nanometer magnetic small is nanometer magnetic particle formed in magnetic bacterial cell, at 35-120nm diameter, while its main component is Fe3O4 or Fe3S4; single magnetic particle is packed by film; and the coupled anti-cancer chemical drug comprises chemotherapy drug, nucleic acid drug, radioactive nuclide or antibody drug. The invention also provides relative production that using physical adsorption couple or based on the active function group contained by smalls and anti-cancer drug, to select right coupler via chemical reaction to couple them. And the smalls has better bioavailability, less side effect, therefore, the anti-cancer drug can be accurately transmitted to ill part via external magnetic field, to reduce the contact between drug and normal organism., to realize target positioning treatment.

The invention relates to the field of biological medicine technology. Traditional anti-tumor antibodies are partly effective for target-positive patients. Chemotherapy drugs with high toxicity can kill tumor cells in a low concentration, but lack targeting. The invention provides a preparation method for an antibody drug conjugate that is anti-CD20-acceptors and inhibits tumor growth, and applications of the antibody drug conjugate in treating B lymphocyte malignant hyperplasia cancer.

The invention belongs to the field of medicine preparation, and in particular to a targeting nanometer drug delivery system aiming at glioma, and a preparation method and application thereof. The drug delivery system comprises target functional molecules, a drug and nano carriers. The target functional molecules are from short chain polypeptide from interleukin 13; the drug is a micromolecular anti-glioma drug; the nano carriers are liposome with surface modified by polyethylene glycol, nanoparticles, polymeric vesicles, polymer micelles and solid lipid nanoparticles; and the drug is enveloped in the nano carriers in an enveloping or covalent connection manner, and the short chain polypeptide is connected with the polyethylene glycol on the surfaces of the nanoparticles through covalent connection. The drug delivery system can promote uptake of the glioma cells by mediated effect of an interleukin 13 receptor alpha 2 on the surfaces of the glioma cells, so as to improve the effect of anti-glioma chemotherapeutics.

The invention discloses an application of miltirone in preparation of antitumor drugs. The miltirone has a structure of formula I; the miltirone serves as an inhibitor of STAT3 (Signal Transducer and Activator of Transcription 3) and is capable of inhibiting growth and proliferation of tumor cells which are abnormally activated by STAT3 so as to cause the apoptosis of the tumor cells and also capable of improving sensibility of cytotoxic drugs and inhibiting formation of tumor vessels. The miltirone with the structure of formula I can inhibit STAT3 kinase Tyr705 phosphorylation level to achieve the functions of accelerating the apoptosis of the tumor cells, improving the sensibility of chemotherapy drugs and inhibiting formation of new vessels; and the proliferation of tumor cells can be significantly inhibited due to the combined combination of the miltirone with low toxicity or non-toxic concentration and adriacin doxorubicin with low toxicity or non-toxic concentration and the combined application of the miltirone and cis-platinum with low toxicity or non-toxic concentration. The functions of the miltirone with the structure of formula I have positive significance to prevention and treatment of tumors.

The objective of the invention is to provide a traditional Chinese medicine granule for treating side effects on an alimentary canal after cancer chemotherapy and a preparation method thereof. The invention is characterized in that the granule is prepared from an active component, a binder and pharmaceutically acceptable adjuvant, and the active component is prepared from the traditional Chinese medicines consisting of 600 to 800 g of milkvetch root, 250 to 350 g of dwarf lilyturf tuber, 150 to 250 g of red ginseng, 150 to 250 g of white atractylodes rhizome fried with bran, 150 to 250 g of Poria cocos, 200 to 300 g of licorice, 200 to 300 g of radix scrophulariae, 200 to 300 g of Chinese angelica, 250 to 350 g of dark plum, 250 to 350 g of prepared pinellia tuber, 200 to 300 g of cablin patchouli herb, 200 to 300 g of dried orange peel and 200 to 300 g of curcuma rhizome. The granule is applicable to cancer patients who vomit or retch because of damage of both qi and yin and rising of stomach qi resulting from damage of the spleen and the stomach by anti-radiogenic cancer and chemotherapy drugs, and the granule can mitigate symptoms like no appetite, tiredness, hypodynamia, a red or light red tongue with little fluid and weak pulse.

The invention relates to a micromolecular conjugate based on RGD polypeptide-chemotherapy drug and a self-assembly nanometer prodrug system thereof, and belongs to the technical field of biological medicine and nanometer medicine. The nanometer prodrug system has the main advantages that (1) the system is formed by RGD polypeptide and an anti-tumor drug through direct covalent connection via micromolecular connecting arms, and the drug loading capacity of the system is improved; (2) the conjugate is self-assembled into a nanometer prodrug using the drug as a hydrophobic inner core and the RGD polypeptide as a hydrophilic outer shell, the active targeting on tumor cells and tumor new vessels is realized through the ligand-receptor mutual action, and the endocytosis is promoted; (3) the stability of the nanometer prodrug system in the body circulation can be ensured through thioether bonds, reduction sensitive bonds and cathepsin B sensitive bonds, and the cytotoxic drug is released when the nanometer prodrug system reaches the tumor microenvironment; and (4) the micromolecular conjugate instead of a macromolecular material is used as a carrier, so that the nanometer prodrug system can favorably and better penetrate into the tumor tissues and cells to achieve better anti-tumor effects.

The invention belongs to the field of pharmaceutical polymer materials, in particular to a degradable polyethyleneimine (PCFC-PEI) cross-linked polymer capable of transferring chemotherapy drugs and gene drugs simultaneously, a preparation method and an application thereof. The PCFC-PEI carrier is a novel carrier material obtained by coupling polycaprolactone poloxamer-polycaprolactone and the polyethyleneimine, wherein the poloxamer is triblock copolymer of polyethylene glycol-polypropylene glycol-polyethylene glycol, the molecular weight thereof is 1100-12500, and the molecular weight of polyethyleneimine section is 600-25000. The degradable polyethyleneimine cross-linked polymer can be used as a novel drug-release carrier, and can transfer the micromolecular chemotherapy drugs and genetherapy drugs simultaneously, thus having wide application prospect in the preparation of anti-tumor drugs.

Provided is a chemotherapy drug mixing device. The device comprises an annular connecting seat, an upper thrusting needle, a lower thrusting needle and a flow valve, a through hole is formed in the middle of the connecting seat from top to bottom, and the upper thrusting needle and lower thrusting needle are respectively arranged at the upper end and lower end of the through hole located in the middle of the annular connecting seat; a cylindrical groove is transversely arranged in the middle of the annular connecting seat, the flow valve comprises a spring, a piston, a push rod, an installation cover and a handle, and a through hole is formed in the middle of the piston from top to bottom; the spring is placed in the left end of the cylindrical groove, the left portion of the push rod is arranged on the right end of the piston, and the installation cover is arranged on the right end of the cylindrical groove, and the right side end of the push rod is sleeved with the handle. The novelproduct is placed in an aseptic bag for storage and use, and the mixing device is made from medical grade aseptic materials to avoid that the material itself influences patient's health. In the process of mixing drug liquid and drug powder, when the drug liquid is transported by the upper thrusting needle and lower thrusting needle, the drug liquid can not be exposed to the air to prevent the outside air from contaminating the mixed drug liquid, the drug liquid flow can be conveniently controlled, and based on the above descriptions, the device has better application prospects.

An association between annexin A3 and the resistance of cancer to the chemicotherapeutic Pt medicines, a method for increasing or decreasing said resistance by changing the annexin A3 expression in cells, a method for testing or diagnosing said resistance, the medicines used for said methods and their components, usage and screening method, and the therapeutic method for the cancers, especially ovarian cancer, are disclosed.

The invention relates to an MUC1 protein nucleic acid aptamer, a complex, a composition and purposes thereof. The invention particularly relates to a nucleic acid aptamer specifically combined with an MUC1 protein, and the sequence of the aptamer is shown as SEQ ID NO.9. The complex is formed by the fact that the MUC1 protein is specifically combined with the nucleic acid aptamer and chemotherapy drugs, or the MUC1 protein, the nucleic acid aptamer and the chemotherapy drugs are wrapped in a nanometer particle. The composition comprises the complex. The nucleic acid aptamer, the complex and the composition have the purpose of tumor resistance and the purpose of tumor targeted radiography.

The invention provides a dual-functional nanoparticle, a soluble microneedle carrying the dual-functional nanoparticle and a preparing method and application. The dual-functional nanoparticle is higher in drug loading capacity and has duplex targeting capacity by adding cationic phospholipids and hyaluronic acid for modification. The dual-functional nanoparticle is composed of a polylactic acid-glycolic acid copolymer, vitamin E succinate, cationic phospholipids, a photosensitizer and a chemotherapy drug. The soluble microneedle is composed of a nanoparticle carrying needle and a substrate. The needle is made of polyvinyl alcohol and povidone, and the substrate is made of polyvinylpyrrolidone. Compared with traditional intratumor injection and tail vein injection, the soluble microneedle carrying the dual-functional nanoparticle and prepared through a multi-step centrifugal method has higher photo-thermal and tumor inhibition effects, and an effective scheme is provided for photo-thermal and chemotherapy combined treatment of superficial tumors.

The invention belongs to the technical field of biological medical polymer materials and discloses a pH- and redox-response macromolecule nano prodrug based on CD44 receptor tumor targeting and preparation method and application thereof. The molecular structure of the macromolecule nano prodrug is as shown in general formula (1), wherein R is one of the structures as shown in the specifications; mand n are respectively side chain polymerization degree and peptide chain polymerization degree, and x is the repetitive unit number; when R1 is phenyl, R2 is acetyl; when R1 is tert-butoxy, R2 is hydrogen. The macromolecule nano prodrug is applicable to the precise delivery of antitumor drugs and the preparation of drugs for inhibiting tumor cell proliferation; after the macromolecule nano prodrug forms nano-micelles in water through self-assembling, tumor tissue is actively identified, the nano-micelles are devoured by cancer cells, the low-pH and high-concentration GSH environments in thecancer cells allow the acylhydrazone bond and disulfide bond in the structure of the nano-micelles to break, the nano-micelles disassemble to accelerate the release of chemotherapy drugs, and the cancer cells are finally killed.

The invention discloses a preparation method and an application of a near-infrared dye functionalized intelligent super-molecule vesicle. According to the preparation method, water solubility column [5] aromatic hydrocarbon (WP5) serves as a main body, a biquaternary ammonium salt functionalized near-infrared dye G based on perylene diimide serves as an objective body, the intelligent super-molecule vesicle is constructed by the aid of acting force of the main body and the objective body between the water solubility column [5] aromatic hydrocarbon and the near-infrared dye, and efficient loading of a drug (hydrophobic anticancer drug adriamycin) can be achieved in the self-assembly process. The near-infrared dye G has excellent near-infrared photo-thermal conversion performance and can serve as a photo-thermal treatment reagent of a tumor. The super-molecule drug load vesicle constructed by the aid of the acting force of the main body and the objective body between the WP5 and the near-infrared dye can stably exist in physiology environments and can rapidly and efficiently release a photo-thermal treatment reagent and a chemotherapy drug in tumor acidic micro-environments, collaborative treatment of photo-thermal treatment / chemotherapy is achieved, the super-molecule drug load vesicle is provided with a good drug delivery system, treatment effect of the tumor is greatly improved, and the super-molecule drug load vesicle has an excellent clinical application prospect.

The invention provides an embolization polymer. The embolization polymer is prepared by performing polymerization reaction initiated by free radicals on micromolecule monomer containing unsaturated double bonds, monomer containing unsaturated double bonds and an optional cross-linking agent; the cross-linking agent is polyfunctionality water-soluble acrylate or acrylamide. The embolization polymeris an ion exchange microsphere carrier and has higher deformation ability and higher drug trapping efficiency and drug loading capacity; meanwhile, a slow release effect is better. The invention further provides a novel blood vessel embolization chemotherapy composite. The embolization chemotherapy composite disclosed by the invention can jointly deliver an embolization agent and chemotherapy drug to a target blood vessel part through a catheter, so that a curative effect of the chemotherapy drug is fully played, peripheral normal tissues are prevented from being damaged, and disease relapsing is reduced.

The invention belongs to the field of three-dimensional tumor cell culture and particularly relates to a three-dimensional drug resistance model of a tumor cell chemotherapy drug and a construction method thereof. The three-dimensional drug resistance model is obtained by dropwise adding an alginate-bladder cancer cell suspension into a divalent / trivalent metal cation salt bath for chelation and preparing cell-loaded alginate gel microspheres for three-dimensional culture. The tumor cell mass obtained by three-dimensional culture has acquired chemotherapy drug resistance, has the performance that the activity of three-dimensional cells is remarkably higher than that of planar cells under the same drug concentration, meanwhile the expression level of an ABCG2 transporter is remarkably improved compared with the expression level of the planar cells, and the chemotherapy drug resistance cell model is successfully constructed. The anti-tumor drug high-throughput screening and evaluation model can be formed by adjusting three-dimensional culture conditions of the cells, meanwhile can also be used for researching the acquired drug resistance mechanism of clinical chemotherapy drugs of tumor cells and find the target of reversal of the clinical chemotherapy drug resistance of bladder cancer cells and has a good application value.

The invention relates to applications of nicotinamide adenine dinucleotide in the field of pharmacy, and more specifically relates to applications of nicotinamide adenine dinucleotide in preparation of a medicine used for curing liver damages caused by chemotherapy drug doxorubicin hydrochloride. NAD<+> is capable of preventing and treating liver damages caused by chemotherapy drug doxorubicin hydrochloride effectively; and it is also found that NAD<+> is capable of killing glioma cells, neuronal tumor cells, gastric cancer cells, renal tumor cells or breast tumor cells effectively, but possesses no killing effect on normal primary cells.